See editorial by Winter et al., on page 4.
UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden?
Article first published online: 24 SEP 2011
© 2011 The Author(s). European Journal of Neurology © 2011 EFNS
European Journal of Neurology
Volume 19, Issue 1, pages 149–154, January 2012
How to Cite
Luengo-Fernandez, R., Leal, J. and Gray, A. M. (2012), UK research expenditure on dementia, heart disease, stroke and cancer: are levels of spending related to disease burden?. European Journal of Neurology, 19: 149–154. doi: 10.1111/j.1468-1331.2011.03500.x
- Issue published online: 19 DEC 2011
- Article first published online: 24 SEP 2011
- Received 9 March 2011 Accepted 11 May 2011
- cost-of-illness study;
- research funding;
Background and purpose: A UK government review recommended that the impact of disease on the population and economy should be assessed to inform health research priorities. This study aims to quantify UK governmental and charity research funding for dementia, cancer, coronary heart disease (CHD) and stroke in 2007/08 and assess whether the levels of research expenditure are aligned with disease and economic burden.
Methods: We identified UK governmental agencies and charities providing health research funding and determined their levels of funding for dementia, cancer, CHD and stroke. Research funding levels were compared to the number of cases, disability-adjusted life years (DALYs) and economic burden. Economic costs were estimated using data on morbidity, mortality, health and social care use, private costs and other related indicators.
Results: Research funding to the four diseases was £833 million, of which £590 million (71%) was devoted to cancer, £169 million (20%) to CHD, £50 million (6%) to dementia and £23 million (4%) to stroke. Cancer received £482 in research funding per 1000 DALYs lost, CHD received £266, dementia received £166, with stroke receiving £71. In terms of economic burden, for every £1 million of health and social care costs attributable to each disease, cancer received £129 269 in research funding, CHD received £73 153, stroke received £8745 and dementia received £4882.
Conclusions: Most health research funding in the UK is currently directed towards cancer. When compared to their burden, our analysis suggests that research spending on dementia and stroke is severely underfunded in comparison with cancer and CHD.